Vosaroxin

Drug Profile

Vosaroxin

Alternative Names: AG-7352; AG-7352 hydrochloride; QINPREZO; SNS-595; SPC-595; Voreloxin

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Dainippon Sumitomo Pharma
  • Developer Sunesis Pharmaceuticals; University of Texas M. D. Anderson Cancer Center; Vanderbilt-Ingram Cancer Center; Washington University School of Medicine; Weill Cornell Medical College
  • Class Antineoplastics; Carboxylic acids; Naphthyridines; Pyrrolidines; Small molecules; Thiazoles
  • Mechanism of Action DNA intercalators; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Acute myeloid leukaemia
  • New Molecular Entity Yes
  • Available For Licensing Yes - Acute myeloid leukaemia; Ovarian cancer

Highest Development Phases

  • Preregistration Acute myeloid leukaemia
  • Phase I/II Myelodysplastic syndromes
  • Preclinical Glioblastoma
  • Discontinued Non-small cell lung cancer; Ovarian cancer; Small cell lung cancer

Most Recent Events

  • 23 Jan 2017 Sunesis Pharmaceuticals plans to meet with Scientific Advisory Group’s Oncology Division (SAG-O) to assist CHMP for MAA approval
  • 03 Dec 2016 Updated efficacy data from the phase III VALOR trial in Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-2016) in December 2016
  • 29 Nov 2016 Preclinical trials in Glioblastoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top